Expand all sections

Ibiglustat

Extended indication

Ziekte van Fabry
Therapeutic value

No judgement
Registration phase

Clinical trials

Product

Active substance

Ibiglustat
Domain

Metabolism and Endocrinology
Main indication

Metabolic diseases
Extended indication

Ziekte van Fabry
Manufacturer

Sanofi
Route of administration

Oral
Therapeutical formulation

Capsule
Budgetting framework

Extramural (GVS)

Registration

Registration route

Centralised (EMA)
Particularity

New medicine
Orphan drug

Yes
Registration phase

Clinical trials
Additional remarks 
Formeel nog geen weesgeneesmiddelstatus verkregen van de EMA.

Therapeutic value

Therapeutic value

No judgement

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.